Work

Table S2 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma

Year: 2023

Type: other

Abstract: Table S2 shows adverse events (regardless of relationship to study drug) by preferred term in {greater than or equal to}10% of patients in total phase 1 population

DOI: 10.1158/1078-0432.22472780

Authors: Monica M. Mita, Patricia M. LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold Keer, Aram Oganesian, Xiang Yao Su, Simone Jueliger, Anthony W. Tolcher

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361817063

Cites:

Cited by:

Related to: 10